#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13780	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2275	602.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1523	1523	C	825	C	757	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13780	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2275	602.6	0	HET	.	.	.	T1412TGGGGG,TGGGGGG	.	1412	1412	T	1751	1751	T	848	TGGGGG,TGGGGGG	604,136	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13780	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2275	602.6	0	HET	.	.	.	C1525T	.	1525	1525	C	1864	1864	C	663	C,T	477,124	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24886	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3606	688.2	0	.	n	.	0	A20C	SNP	20	20	A	368	368	C	497	C,A	334,135	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24886	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3606	688.2	0	.	n	.	0	T695C	SNP	695	695	T	1043	1043	C	767	C,T,A	715,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24886	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3606	688.2	0	.	n	.	0	A1638G	SNP	1638	1638	A	1986	1986	G	874	G,T	814,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24886	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3606	688.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2319	2319	C	763	C,A,T	691,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24886	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3606	688.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2393	2393	A	824	A	772	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24886	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3606	688.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2945	2945	C	794	C	740	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	24886	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3606	688.2	0	HET	.	.	.	C2626CGGGGG,CGGGG	.	2626	2626	C	2974	2974	C	791	CGGGGG,CGGGG	555,158	.	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1882	folP	855	855	100.0	folP.l15.c4.ctg.1	1645	113.8	1	SNP	p	R229S	1	.	.	685	687	AGC	1098	1100	AGC	204;205;207	A;G;C	190;192;191	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4784	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3279	145.2	1	SNP	p	S91F	1	.	.	271	273	TTC	562	564	TTC	159;160;158	T;T;C,T	148;147;145,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4784	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3279	145.2	1	SNP	p	D95G	1	.	.	283	285	GGC	574	576	GGC	161;157;155	G;G;C	146;141;139	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4784	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3279	145.2	1	SNP	p	G95N	0	.	.	283	285	GGC	574	576	GGC	161;157;155	G;G;C	146;141;139	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1476	mtrR	633	633	99.84	mtrR.l6.c30.ctg.1	1478	99.6	0	.	p	.	0	F184L	NONSYN	550	552	TTC	977	979	TTG	166;171;172	T;T;G	146;151;151	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1476	mtrR	633	633	99.84	mtrR.l6.c30.ctg.1	1478	99.6	1	SNP	p	G45D	0	.	.	133	135	GGC	560	562	GGC	197;197;197	G;G;C	180;179;179	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	762	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	920	81.8	0	.	n	.	0	A197.	DEL	197	197	A	492	492	A	180	A	172	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4772	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3064	155.1	1	SNP	p	D86N	0	.	.	256	258	GAC	700	702	GAC	179;182;185	G;A;C	160;157;167	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4772	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3064	155.1	1	SNP	p	R87W	0	.	.	259	261	CGT	703	705	CGT	185;188;191	C,T;G;T	170,1;174;173	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4772	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3064	155.1	1	SNP	p	R87I	0	.	.	259	261	CGT	703	705	CGT	185;188;191	C,T;G;T	170,1;174;173	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4772	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3064	155.1	1	SNP	p	S87R	1	.	.	259	261	CGT	703	705	CGT	185;188;191	C,T;G;T	170,1;174;173	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4772	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3064	155.1	1	SNP	p	S88P	0	.	.	262	264	TCC	706	708	TCC	190;190;192	T;C;C	173;175;178	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3820	parE	1986	1986	100.0	parE.l15.c30.ctg.1	2634	144.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1458	1460	GGC	176;173;172	G;G;C	161;160;160	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	3668	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2304	158.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1185	1187	GCA	183;180;180	G;C;A	165;163;169	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3668	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2304	158.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1188	1190	ATC	183;183;186	A;T;C	170;169;172	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3668	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2304	158.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1200	1202	GTG	189;189;189	G,A;T;G	178,1;174;178	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3668	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2304	158.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1200	1202	GTG	189;189;189	G,A;T;G	178,1;174;178	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3668	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2304	158.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1704	1706	ACC	210;209;209	A;C;C,A	187;190;189,1	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3668	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2304	158.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1758	1760	GCG	205;204;203	G;C;G	179;160;166	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3668	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2304	158.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1758	1760	GCG	205;204;203	G;C;G	179;160;166	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3668	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2304	158.1	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1881	1883	AGC	154;152;152	A;G;C	142;141;139	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3668	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2304	158.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1890	1892	GGC	142;142;140	G;G;C	134;130;130	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3668	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2304	158.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1908	1910	CCG	117;116;114	C,G;C;G	84,2;85;83	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5168	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3076	167.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1625	1627	CCG	191;191;191	C,T;C;G	165,1;170;165	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1972	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1677	116.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	528	528	C	147	C	135	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2644	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1526	172.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	449	451	GAA	234;235;236	G;A;A	214;220;221	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2644	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1526	172.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	737	739	GAT	223;222;224	G;A;T	209;205;206	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2644	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1526	172.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	860	862	TCA	219;219;223	T;C;A	198;197;202	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2644	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1526	172.0	0	.	p	.	0	D212G	NONSYN	634	636	GAT	971	973	GGT	219;218;216	G;G;T	212;212;200	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2644	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1526	172.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	989	991	GTC	210;209;208	G;T;C	197;195;193	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2644	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1526	172.0	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1001	1003	TCT	207;206;205	T;C;T	194;196;192	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2644	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1526	172.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1319	1321	GCA	201;202;205	G;C;A	187;186;188	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2644	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1526	172.0	1	SNP	p	G120K	1	.	.	358	360	AAG	695	697	AAG	232;234;235	A;A;G,T	216;217;218,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2644	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1526	172.0	1	SNP	p	D121N	0	.	.	361	363	GAC	698	700	GAC	233;232;233	G;A;C	219;214;218	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2644	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1526	172.0	1	SNP	p	A121D	1	.	.	361	363	GAC	698	700	GAC	233;232;233	G;A;C	219;214;218	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9820	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	4885	200.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1100	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1181	92.6	1	SNP	p	V57M	1	.	.	169	171	ATG	607	609	ATG	220;222;222	A;T;G	210;210;209	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
